A diagnostic method for predicting quantitatively whether a human tumor will be responsive or resistant (non-responsive) to treatment with the VEGF inhibitor, tivozanib (AV-951), is disclosed. The test is based on application of an algorithm to measurements of expression levels of the genes in a predictive gene set.

 
Web www.patentalert.com

< Method for therapy of rheumatoid arthritis

> Formulations comprising antisense nucleotides to connexins

> Disease susceptibility gene for rheumatoid arthritis, protein thereof, evaluation method and evaluation kit for evaluating onset possibility of rheumatoid arthritis by using those, and remedy and curing medicine for rheumatoid arthritis
~ 00558